An oral peptide that blocks the interleukin-23 receptor demonstrated durable long-term efficacy in patients with moderately ...

A study presented at ACG reveals low dermatology and cervical cancer screening rates in patients with ulcerative colitis and ...

Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by ...

Researchers at Georgia State University identified two metabolite-inspired compounds that showed enhanced anti-inflammatory ...

Thursday, Eli Lilly and Company ( LLY) announced new data analyses showing that, at one year, patients with moderately to severely active ulcerative colitis and Crohn's disease treated with Omvoh ...

A Cedars-Sinai-led clinical trial found that a once-daily oral medication significantly outperformed placebo in treating adults with moderate to severe ulcerative colitis. The results were published ...

A Turkish study finds that cytomegalovirus DNA in colon tissue is associated with severe disease activity and corticosteroid ...

Equillium receives Australian clearance to start the first-in-human EQ504 trial for ulcerative colitis. Read how dosing ...

Inc. today announced that two analyses evaluating ZYMFENTRA® (infliximab-dyyb) will be presented in oral presentations on ...

RBC kept its GBp 1,975 target on October 13, 2026. GSK stock faces October 28 results after GBP 8.41 billion second-quarter ...

This article contains specific descriptions of diarrhea and bowel movements. Please be aware of this if you are sensitive to ...

ABIVAX's obefazimod showed 51% clinical remission vs. 10% placebo in 44-week UC trial, claiming largest phase 3 ...